Who’s Hired? Teva’s Head In Israel Departs
As Former Teva Canada Head Takes On A New Role
Teva’s country head for its local Israeli operation has moved on, with Teva promoting his successor from within. Meanwhile, Doug Sommerville, the former head of Teva Canada, has taken a new role dedicated to efforts to tackle the accelerating COVID-19 crisis.
You may also be interested in...
Samsung Bioepis is the latest company to stare down a lawsuit from Genentech over Avastin patents in the US. The Korean firm is aiming to be amongst the early biosimilar movers, after the market formed a year ago.
Sandoz has failed to overturn on appeal an invalidity ruling for two patents covering Enbrel in the US, barring a path to market for its Erelzi biosimilar, potentially until patent expiry in 2029.
Biosimilar competition to Regeneron’s Eylea (aflibercept) eye-disease biologic may emerge as early as 2023, with at least three firms moving candidates to Phase III development following Samsung Bioepis’ study initiation.